Manocept + dexamethasone

**Manocept + dexamethasone** is a preclinical, macrophage-targeted therapeutic construct developed from Navidea's Manocept platform. It uses a mannosylated dextran carrier designed to bind the CD206 mannose receptor on activated macrophages and deliver dexamethasone through a degradable linker. The intended strategy is to concentrate glucocorticoid anti-inflammatory activity in CD206-expressing macrophages, potentially improving local therapeutic activity while reducing systemic corticosteroid exposure. Public company disclosures describe preclinical evaluation in macrophage studies and animal models of oncology and inflammatory indications.

Other names

dexamethasone-containing Manocept therapeutic construct